BNP Paribas Arbitrage SA lowered its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 5.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,236 shares of the company’s stock after selling 3,566 shares during the period. BNP Paribas Arbitrage SA’s holdings in Catalent were worth $2,365,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in CTLT. Acrospire Investment Management LLC boosted its holdings in Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after acquiring an additional 1,300 shares in the last quarter. Quantbot Technologies LP boosted its holdings in Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after acquiring an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. bought a new position in Catalent in the third quarter worth approximately $164,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after acquiring an additional 559 shares in the last quarter. Finally, Advisor Group Inc. lifted its holdings in shares of Catalent by 1.3% in the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares in the last quarter. Institutional investors and hedge funds own 99.49% of the company’s stock.
A number of brokerages recently commented on CTLT. BidaskClub upgraded Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Piper Jaffray Companies reiterated a “buy” rating and set a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. J P Morgan Chase & Co reissued a “buy” rating and issued a $40.00 target price on shares of Catalent in a research report on Tuesday, August 29th. Finally, Jefferies Group reissued a “hold” rating and issued a $38.00 target price (up from $35.00) on shares of Catalent in a research report on Tuesday, August 29th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $44.25.
Catalent, Inc. (NYSE:CTLT) traded up $0.11 during trading hours on Thursday, reaching $39.34. The company had a trading volume of 716,429 shares, compared to its average volume of 911,027. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. Catalent, Inc. has a 12 month low of $23.41 and a 12 month high of $43.39. The company has a market capitalization of $5,055.30, a price-to-earnings ratio of 26.61, a price-to-earnings-growth ratio of 2.45 and a beta of 1.41.
Catalent (NYSE:CTLT) last released its earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million during the quarter, compared to analyst estimates of $490.75 million. During the same quarter in the previous year, the company posted $0.16 EPS. Catalent’s revenue for the quarter was up 23.0% on a year-over-year basis. equities analysts predict that Catalent, Inc. will post 1.46 earnings per share for the current year.
In other Catalent news, Director Uwe Roehrhoff purchased 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average price of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.70% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/07/catalent-inc-ctlt-shares-sold-by-bnp-paribas-arbitrage-sa.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.